Structure Therapeutics Q3 loss widens on higher R&D costs

Overview

• US biopharma firm's Q3 net loss widened yr/yr as operating expenses increased

• Higher R&D and G&A costs driven by clinical trial activity and expanded operations

• Company ended Q3 with $1.2 bln cash, expects runway through 2028

Outlook

• Company expects topline data from Phase 3 aleniglipron trials in 2H 2028

• Structure Therapeutics expects additional aleniglipron data from supplementary studies in Q4 2026

• Company expects topline data from ACCG-2671 MAD clinical trial in 1H 2027

Result Drivers

• CLINICAL TRIAL COSTS - Co said higher R&D expenses were mainly due to increased clinical trial costs, preclinical R&D and employee expenses

• INFRASTRUCTURE EXPANSION - Higher G&A expenses attributed to increased employee costs as co expanded infrastructure to support operations growth

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Structure Therapeutics Inc. is $110.00, about 440.5% above its November 6 closing price of $20.35

Reuters Recommended Reads

• Nov 9 - Neurogene Q3 net loss widens on higher R&D and G&A costs

• Nov 9 - Bicara Therapeutics Q3 net loss widens on higher R&D costs

• Nov 9 - Compass Therapeutics Q3 net loss widens on higher R&D expenses

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)